Yingen Bio

Yingen Biotech is a clinical-stage biopharmaceutical company headquartered in Suzhou, China, focused on developing innovative treatments for metabolic diseases such as diabetes and obesity. The company's lead asset, Supaglutide (YN011), is a long-acting GLP-1 receptor agonist that has entered Phase 3 clinical trials for type 2 diabetes and is being evaluated for weight management. Yingen Biotech utilizes a proprietary technology platform to engineer humanized, long-acting peptides and proteins with optimized pharmacokinetic properties. The company's pipeline also includes multi-target agonists, such as GLP-1/GIP and GLP-1/Glucagon dual agonists, aimed at addressing complex metabolic disorders. With a strong focus on endocrinology, Yingen Biotech aims to provide more effective and convenient therapeutic options for patients worldwide.